دورية أكاديمية
Rates of Adverse Events in Patients With Ulcerative Colitis Undergoing Colectomy During Treatment With Tofacitinib vs Biologics: A Multicenter Observational Study.
| العنوان: | Rates of Adverse Events in Patients With Ulcerative Colitis Undergoing Colectomy During Treatment With Tofacitinib vs Biologics: A Multicenter Observational Study. |
|---|---|
| المؤلفون: | Dragoni G; IBD Referral Centre, Careggi University Hospital, Florence, Italy.; Department of Experimental and Clinical Biomedical Sciences 'Mario Serio,' University of Florence, Florence, Italy., Innocenti T; IBD Referral Centre, Careggi University Hospital, Florence, Italy.; Department of Experimental and Clinical Biomedical Sciences 'Mario Serio,' University of Florence, Florence, Italy., Amiot A; Department of Gastroenterology, Henri Mondor University Hospital, Paris Est-Creteil University, Creteil, France., Castiglione F; Department of Clinical Medicine and Surgery, 'Federico II' University of Naples, Naples, Italy., Melotti L; Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy., Festa S; IBD Unit, 'San Filippo Neri' Hospital, Rome, Italy., Savarino EV; Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy., Truyens M; Department of Gastroenterology, Ghent University Hospital, Ghent, Belgium., Argyriou K; Department of Gastroenterology, University Hospital of Larisa, Larissa, Greece., Noviello D; Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy., Molnar T; Department of Gastroenterology, Albert Szent-Györgyi Medical School, University of Szeged, Szeged, Hungary., Bouillon V; Department of Gastroenterology, Erasme University Hospital, Brussels, Belgium., Bezzio C; IBD Center, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy., Eder P; Department of Gastroenterology, Dietetics and Internal Medicine-Poznań University of Medical Sciences, Heliodor Święcicki University Hospital, Poznań, Poland., Fernandes S; Department of Gastroenterology and Hepatology, Hospital de Santa Maria, Centro Hospitalar Universitário de Lisboa Norte, Lisboa, Portugal.; Clínica Universitária da Faculdade de Medicina de Lisboa, Lisboa, Portugal., Kagramanova A; Moscow Clinical Scientific Center named after A.S. Loginov, Moscow, Russian Federation., Armuzzi A; IBD Center, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy., Oliveira R; Gastroenterology Department, Algarve University Hospital Centre-Portimão Unit, Algarve, Portugal., Viola A; IBD-Unit, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy., Ribaldone DG; Division of Gastroenterology, Department of Medical Sciences, University of Turin, Turin, Italy., Drygiannakis I; Department of Gastroenterology, University Hospital of Heraklion, Heraklion, Greece., Viganò C; Division of Gastroenterology, Center for Autoimmune Liver Diseases, Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.; European Reference Network on Hepatological Diseases (ERN RARE-LIVER), Fondazione IRCCS San Gerardo dei Tintori, Monza, Italia., Calella F; SOC Gastroenterologia ed endoscopia digestiva, Azienda USL Toscana Centro, Ospedale 'San Giuseppe,' Empoli, Italy., Gravina AG; Hepatogastroenterology Unit, Department of Precision Medicine, University of Campania 'Luigi Vanvitelli,' Naples, Italy., Pugliese D; CEMAD, IBD Unit, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario 'A. Gemelli' IRCCS, Rome, Italy., Chaparro M; Gastroenterology Unit, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-Princesa), Universidad Autónoma de Madrid (UAM), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Madrid, Spain., Ellul P; Department of Medicine, Division of Gastroenterology, Mater Dei Hospital, Msida, Malta., Vieujean S; Hepato-Gastroenterology and Digestive Oncology, University Hospital CHU of Liège, Liège, Belgium., Milla M; IBD Referral Centre, Careggi University Hospital, Florence, Italy., Caprioli F; Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy.; Gastroenterology and Endoscopy Unit, Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico di Milano, Milan, Italy. |
| مؤلفون مشاركون: | “TOFA-poSTOP” Study Group |
| المصدر: | The American journal of gastroenterology [Am J Gastroenterol] 2024 Aug 01; Vol. 119 (8), pp. 1525-1535. Date of Electronic Publication: 2024 Feb 02. |
| نوع المنشور: | Journal Article; Multicenter Study; Observational Study; Comparative Study |
| اللغة: | English |
| بيانات الدورية: | Publisher: Wolters Kluwer Health Country of Publication: United States NLM ID: 0421030 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1572-0241 (Electronic) Linking ISSN: 00029270 NLM ISO Abbreviation: Am J Gastroenterol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: <2019-> : [Philadelphia, PA] : Wolters Kluwer Health Original Publication: New York, Elsevier Science, -2003. |
| مواضيع طبية MeSH: | Colitis, Ulcerative*/surgery , Colitis, Ulcerative*/drug therapy , Colectomy* , Piperidines*/therapeutic use , Piperidines*/adverse effects , Pyrimidines*/therapeutic use , Pyrimidines*/adverse effects , Biological Products*/therapeutic use , Biological Products*/adverse effects , Postoperative Complications*/epidemiology, Humans ; Male ; Female ; Retrospective Studies ; Middle Aged ; Adult ; Antibodies, Monoclonal, Humanized/therapeutic use ; Antibodies, Monoclonal, Humanized/adverse effects ; Patient Readmission/statistics & numerical data ; Pyrroles/therapeutic use ; Pyrroles/adverse effects ; Venous Thromboembolism/epidemiology ; Reoperation/statistics & numerical data ; Surgical Wound Infection/epidemiology ; Aged |
| مستخلص: | Introduction: Patients with ulcerative colitis (UC) receiving immunosuppressive drugs are at substantial risk of colectomy. We aimed to assess the risk of postoperative complications of tofacitinib exposure before colectomy in comparison with biologics. Methods: A multicenter, retrospective, observational study was conducted in patients with UC who underwent total colectomy for medically refractory disease, exposed to tofacitinib or a biologic before surgery. Primary outcome was the occurrence of any complication within 30 (early) and 90 (late) days after surgery. Secondary outcomes were the occurrence of infections, sepsis, surgical site complications, venous thromboembolic events (VTE), hospital readmissions, and redo surgery within the same timepoints. Results: Three hundred one patients (64 tofacitinib, 162 anti-tumor necrosis factor-α agents, 54 vedolizumab, and 21 ustekinumab) were included. No significant differences were reported in any outcome, except for a higher rate of early VTE with anti-tumor necrosis factor-α agents ( P = 0.047) and of late VTE with vedolizumab ( P = 0.03). In the multivariate analysis, drug class was not associated with a higher risk of any early and late complications. Urgent colectomy increased the risk of any early (odds ratio [OR] 1.92, 95% confidence interval [CI] 1.06-3.48) complications, early hospital readmission (OR 4.79, 95% CI 1.12-20.58), and early redo surgery (OR 7.49, 95% CI 1.17-47.85). A high steroid dose increased the risk of any early complications (OR 1.96, 95% CI 1.08-3.57), early surgical site complications (OR 2.03, 95% CI 1.01-4.09), and early redo surgery (OR 7.52, 95% CI 1.42-39.82). Laparoscopic surgery decreased the risk of any early complications (OR 0.54, 95% CI 0.29-1.00), early infections (OR 0.39, 95% CI 0.18-0.85), and late hospital readmissions (OR 0.34, 95% CI 0.12-1.00). Discussion: Preoperative tofacitinib treatment demonstrated a postoperative safety profile comparable with biologics in patients with UC undergoing colectomy. (Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology.) |
| References: | Ungaro R, Mehandru S, Allen PB, et al. Ulcerative colitis. Lancet 2017;389:1756–70. Vieujean S, D'Amico F, Netter P, et al. Landscape of new drugs and targets in inflammatory bowel disease. United Eur Gastroenterol J 2022;10:1129–66. Murthy SK, Begum J, Benchimol EI, et al. Introduction of anti-TNF therapy has not yielded expected declines in hospitalisation and intestinal resection rates in inflammatory bowel diseases: A population-based interrupted time series study. Gut 2020;69:274–82. Sandborn WJ, Su C, Sands BE, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2017;376:1723–36. D'Amico F, Parigi TL, Fiorino G, et al. Tofacitinib in the treatment of ulcerative colitis: Efficacy and safety from clinical trials to real-world experience. Therap Adv Gastroenterol 2019;12:1756284819848631. Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med 2022;386:316–26. European Medicines Agency. EMA confirms Xeljanz to be used with caution in patients at high risk of blood clots. 2019 ( https://www.ema.europa.eu/en/news/ema-confirms-xeljanz-be-used-caution-patients-high-risk-blood-clots ). Accessed July 1, 2023. U.S. Food and Drug Administration. FDA approves Boxed Warning about increased risk of blood clots and death with higher dose of arthritis and ulcerative colitis medicine tofacitinib (Xeljanz, Xeljanz XR). 2019 ( https://www.fda.gov/drugs/drug-safety-and-availability/fda-approves-boxed-warning-about-increased-risk-blood-clots-and-death-higher-dose-arthritis-and ). Accessed July 1, 2023. Olivera PA, Lasa JS, Bonovas S, et al. Safety of Janus kinase inhibitors in patients with inflammatory bowel diseases or other immune-mediated diseases: A systematic review and meta-analysis. Gastroenterology 2020;158:1554–73.e12. Lasa JS, Olivera PA, Danese S, et al. Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: A systematic review and network meta-analysis. Lancet Gastroenterol Hepatol 2022;7:161–70. Lightner AL, Vaidya P, Holubar S, et al. Perioperative safety of tofacitinib in surgical ulcerative colitis patients. Colorectal Dis 2021;23:2085–90. Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: Building an international community of software platform partners. J Biomed Inform 2019;95:103208. Cohen BL, Fleshner P, Kane SV, et al. Prospective cohort study to investigate the safety of preoperative tumor necrosis factor inhibitor exposure in patients with inflammatory bowel disease undergoing intra-abdominal surgery. Gastroenterology 2022;163:204–21. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a working party of the 2005 Montreal world congress of gastroenterology. Can J Gastroenterol 2005;19(Suppl A):5a–36a. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 1987;40:373–83. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987;317:1625–9. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462–76. Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 2016;315:801–10. Barnes EL, Lightner AL, Regueiro M. Perioperative and postoperative management of patients with Crohn's disease and ulcerative colitis. Clin Gastroenterol Hepatol 2020;18:1356–66. Poylin VY, Serrato JC, Pastrana Del Valle J, et al. Vedolizumab does not increase perioperative surgical complications in patients with inflammatory bowel disease, cohort study. Intest Res 2022;20:72–7. Novello M, Stocchi L, Steele SR, et al. Case-matched comparison of postoperative outcomes following surgery for inflammatory bowel disease after exposure to vedolizumab vs other biologics. J Crohns Colitis 2020;14:185–91. García MJ, Rivero M, Miranda-Bautista J, et al. Impact of biological agents on postsurgical complications in inflammatory bowel disease: A multicentre study of Geteccu. J Clin Med 2021;10. Sandborn WJ, Panés J, D'Haens GR, et al. Safety of tofacitinib for treatment of ulcerative colitis, based on 4.4 years of data from global clinical trials. Clin Gastroenterol Hepatol 2019;17:1541–50. Shepard J, Ward W, Milstone A, et al. Financial impact of surgical site infections on hospitals: The hospital management perspective. JAMA Surg 2013;148:907–14. Grainge MJ, West J, Card TR. Venous thromboembolism during active disease and remission in inflammatory bowel disease: A cohort study. Lancet 2010;375:657–63. Carvello M, Watfah J, Spinelli A. The management of the hospitalized ulcerative colitis patient, the medical-surgical conundrum. Curr Gastroenterol Rep 2021;23:25. Øresland T, Bemelman WA, Sampietro GM, et al. European evidence based consensus on surgery for ulcerative colitis. J Crohns Colitis 2015;9:4–25. Randall J, Singh B, Warren BF, et al. Delayed surgery for acute severe colitis is associated with increased risk of postoperative complications. Br J Surg 2010;97:404–9. Vasudevan A, Arachchi A, Scanlon C, et al. A comparison of long-term healthcare utilization and costs in patients with acute severe ulcerative colitis receiving infliximab versus early colectomy. Ther Adv Chronic Dis 2019;10:2040622319825595. Leeds IL, Truta B, Parian AM, et al. Early surgical intervention for acute ulcerative colitis is associated with improved postoperative outcomes. J Gastrointest Surg 2017;21:1675–82. Fleming FJ, Francone TD, Kim MJ, et al. A laparoscopic approach does reduce short-term complications in patients undergoing ileal pouch-anal anastomosis. Dis Colon Rectum 2011;54:176–82. Indar AA, Efron JE, Young-Fadok TM. Laparoscopic ileal pouch-anal anastomosis reduces abdominal and pelvic adhesions. Surg Endosc 2009;23:174–7. Mark-Christensen A, Troelsen FS, Tøttrup A, et al. Short-term outcomes following total colectomy for inflammatory bowel disease in Denmark after implementation of laparoscopy: A nationwide population-based study. Colorectal Dis 2023;25:1802–11. Mège D, Figueiredo MN, Manceau G, et al. Three-stage laparoscopic ileal pouch-anal anastomosis is the best approach for high-risk patients with inflammatory bowel disease: An analysis of 185 consecutive patients. J Crohns Colitis 2016;10:898–904. Lee GC, Deery SE, Kunitake H, et al. Comparable perioperative outcomes, long-term outcomes, and quality of life in a retrospective analysis of ulcerative colitis patients following 2-stage versus 3-stage proctocolectomy with ileal pouch-anal anastomosis. Int J Colorectal Dis 2019;34:491–9. Hicks CW, Hodin RA, Bordeianou L. Possible overuse of 3-stage procedures for active ulcerative colitis. JAMA Surg 2013;148:658–64. Spinelli A, Bonovas S, Burisch J, et al. ECCO guidelines on therapeutics in ulcerative colitis: Surgical treatment. J Crohns Colitis 2022;16:179–89. Morar PS, Hodgkinson JD, Thalayasingam S, et al. Determining predictors for intra-abdominal septic complications following ileocolonic resection for Crohn's disease-considerations in pre-operative and peri-operative optimisation techniques to improve outcome. J Crohns Colitis 2015;9:483–91. Inoue Y, Katoh T, Masuda S, et al. Perioperative complications of abdominal surgery in smokers. J Anesth 2020;34:712–8. Møller AM, Villebro N, Pedersen T, et al. Effect of preoperative smoking intervention on postoperative complications: A randomised clinical trial. Lancet 2002;359:114–7. |
| فهرسة مساهمة: | Investigator: A Aratari; F Belli; I Botto; E Bretto; A Cremer; A Dal Buono; DA Giorgi; JP Gisbert; A Kapsoritakis; I Koutroubakis; A Laffusa; T Lobaton; OM Nardone; J Neves; K Oleg; R Pellegrino; G Poggioli; M Rottoli; S Saibeni |
| المشرفين على المادة: | 87LA6FU830 (tofacitinib) 0 (Piperidines) 0 (Pyrimidines) 0 (Biological Products) 9RV78Q2002 (vedolizumab) 0 (Antibodies, Monoclonal, Humanized) 0 (Pyrroles) |
| تواريخ الأحداث: | Date Created: 20240202 Date Completed: 20240802 Latest Revision: 20240802 |
| رمز التحديث: | 20240802 |
| مُعرف محوري في PubMed: | PMC11288395 |
| DOI: | 10.14309/ajg.0000000000002676 |
| PMID: | 38305302 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1572-0241 |
|---|---|
| DOI: | 10.14309/ajg.0000000000002676 |